Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

Also called NCT02413515

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 278 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02413515
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02413515. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03-26 (actual); primary completion 2016-08-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
Acronym
ADEPT
Condition
Hypertension
Intervention (Drug)
Nifedipine (Adalat GITS, BAY1040)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02413515
Content hash
b8d08534f5e28b88d40a6525292c899ba77d17b47052b95834e8c3ad8b440994